PMID- 31807971
OWN - NLM
STAT- MEDLINE
DCOM- 20200227
LR  - 20200227
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Linking)
VI  - 38
IP  - 4
DP  - 2019 Dec
TI  - MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic 
      leukemia: a systematic review.
PG  - 771-782
LID - 10.1007/s10555-019-09826-0 [doi]
AB  - Recent studies suggest abnormal microRNA (miRNA) expression may have potential 
      prognostic value in childhood acute lymphoblastic leukemia (ALL). In this 
      systematic review, we searched different databases (PubMed, ASH, ASCO, and SIOP) 
      for studies published from 2008 to 2018 that evaluated the prognostic impact of 
      miRNAs in childhood ALL. We also used DIANA-miRPath v3.0 to further characterize 
      the functional role of the significant prognostic miRNAs identified in our 
      systematic review. Here we evaluate 15 studies with a total of 38 different 
      miRNAs and 1545 children with B-cell ALL (B-ALL) or T-cell ALL (T-ALL) recruited 
      over approximately 3 decades (1984-2016) with different treatment protocols and 
      ethnicities. Out of the 15 studies examined, 14 reported 32 dysregulated miRNAs 
      with significant prognostic impact in pediatric ALL patients. Only one Brazilian 
      study reported no significant prognostic effect of 7 miRNAs, while the seventh 
      miRNA (miR-100) showed prognostic significance in a Chinese study. Using 
      DIANA-TarBase v7.0 of DIANA-miRPath v3.0, pathway enrichment analysis revealed 25 
      miRNAs modulated 24 molecular pathways involved in cancer development. To remove 
      the effect of salvage therapy, 9 studies carried out multivariate cox regression 
      analysis for both relapse-free survival and disease-free survival to develop a 
      panel of 23 miRNAs acting as independent prognostic biomarkers. To enhance the 
      clinical application, utility, and validity of the miRNAs discussed here, their 
      potential prognostic value should be confirmed in larger cohort studies within 
      different ethnicities and different ALL protocols adjusted for other contemporary 
      validated prognostic factors in childhood ALL.
FAU - Rashed, Wafaa M
AU  - Rashed WM
AUID- ORCID: 0000-0001-7531-2840
AD  - Clinical Trials Unit, Clinical Research, Children's Cancer Hospital Egypt-57357 
      (CCHE-57357), Cairo, Egypt. wafaaanor@gmail.com.
FAU - Hamza, Mahmoud M
AU  - Hamza MM
AD  - Biostatistics Unit, Clinical Research, Children's Cancer Hospital Egypt-57357 
      (CCHE-57357), Cairo, Egypt.
FAU - Matboli, Marwa
AU  - Matboli M
AD  - Biochemistry Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
FAU - Salem, Sherin I
AU  - Salem SI
AD  - Cytogenetics Department, Children's Cancer Hospital Egypt-57357 (CCHE-57357), 
      Cairo, Egypt.
AD  - National Cancer Institute, Cairo University, Giza, Egypt.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Child
MH  - Humans
MH  - MicroRNAs/biosynthesis/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia
OT  - MicroRNA
OT  - Prognostic biomarker
EDAT- 2019/12/07 06:00
MHDA- 2020/02/28 06:00
CRDT- 2019/12/07 06:00
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2020/02/28 06:00 [medline]
PHST- 2019/12/07 06:00 [entrez]
AID - 10.1007/s10555-019-09826-0 [pii]
AID - 10.1007/s10555-019-09826-0 [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2019 Dec;38(4):771-782. doi: 10.1007/s10555-019-09826-0.